Subscribe to Pro or Enterprise plans to unlock this feature.
Become a smarter investor today.
Become a smarter investor today.
This statistic highlights OPKO Health’s Revenue Breakdown Worldwide, split across the US, Chile, Spain, Ireland, Mexico, Israel, and Other regions, reported on a quarterly basis from Q1 2016 onwards.
OPKO Health’s Revenue Breakdown Worldwide
The following table highlights OPKO Health’s Revenue Breakdown Worldwide for Q3 2020, Q2 2021 & Q3 2021:
|Region||Q3 2020||Q2 2021||Q3 2021||Contribution in Q3 2021|
(All figures are in millions, except percentages)
The United States contributes the highest revenue, generating about 90% in each quarter. In this region, the company recorded the highest revenue in Q1 2021, of about $512 million, which has been declining since then. On a QoQ basis, OPKO Health’s revenue from the U.S. region decreased by 11.8%. Even on a YoY basis, there was a fall of 9.9% in the revenue generated. However, the revenue generated is still twice more than what was being earned before the pandemic.
Chile contributes the second-highest revenue to the company. The revenue from this region as well, boosted post the pandemic. On a YoY basis, there was an increase of 49% in the revenue generated. However, on a QoQ basis, there was a decline of 11.6% in the revenue generated.
This region contributes 1.48% of the total revenue. On a QoQ basis, there was an increase of 5.1% in the revenue generated. Even on a YoY basis, there was an increase of 54.2% in the revenue generated from this region.
This region contributes 1.41% of the total revenue. The company generated a record-high revenue in Q2 2016, of $71.79 million. This spike was due to the acquisition of EirGen, an Ireland-based company. On a QoQ basis, there was an increase of 5.1% in the revenue generated. Even on a YoY basis, there was an increase of 54.2% in the revenue generated from this region. However, since 2016, the revenue has been declining and fell by greater margins during the pandemic.
This region contributes 0.82% of the company’s total revenue. There has been an increasing trend in the revenue generated with some downfalls in certain quarters. On a QoQ basis, there was an increase of 3.9% in the revenue generated. Even on a YoY basis, there was an increase of 38.6% in the revenue generated from this region.
This region contributes 0.08% of the company’s total revenue. There was a sharp incline in the revenue generated, with $7.65 million earned in Q2 2017. However, there has been a decreasing trend has been observed, with the least revenue earned in Q4 each year. On a QoQ basis, the revenue halved to $0.31 million. Even on a YoY basis, there was a decline of 72.3% in the revenue generated.
This category represents all other countries than the ones mentioned above. A minimal 0.03% contribution to the total revenue, comes from this region. However, since 2016, there is an increasing trend observed.
About the Company
OPKO Health is a medical test and medication company focused on diagnostics and pharmaceuticals, listed in the NYSE with the stock ticker OPK. They are a diversified healthcare company that seeks to establish industry-leading positions in large and rapidly growing medical markets.
OPKO Health owns BioReference Laboratories, Inc., one of the largest full-service laboratories in the U.S. Under their pharmaceutical business, they own Rayaldee, which is used in the treatment of stage 3 or 4 chronic kidney disease for adults. It is even used for the treatment of vitamin D insufficiency. OPKO Health is even developing Somatrogon, a once-weekly human growth hormone injection, in a partnership with Pfizer.
The company has even established pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. Apart from this, they own a commercial supply pharmaceutical company as well as a global supply chain operation and holding company in Ireland. They even own a specialty active pharmaceutical ingredients (API) manufacturer in Israel.
Did you like OPKO Health’s Revenue Breakdown Worldwide statistic?
Access more such KPI data points and segment financials on thousands of US stocks, with Business Quant.
You can get started here.
Always know what you’ll pay. No hidden costs or surprises.
* Billed annually, local taxes extra.
* Local taxes extra.